Harry Clifford

Harry Clifford is the HealthTech Entrepreneur in Residence at Oxford Science Enterprises, based in Cambridge, United Kingdom. He previously co-founded and served as Chief Technology Officer of CCG.ai, a Y Combinator S17 precision oncology startup that raised $4.1 million before being acquired by Dante Labs in June 2021. Following this successful exit, he operated as Vice President of Oncology at Dante Labs and later worked as a Product Manager for NVIDIA Clara Parabricks. Clifford holds a Doctor of Philosophy in Next Generation Sequencing from the University of Oxford, completed postdoctoral research at the University of Cambridge, and previously worked as a bioinformatician at hVIVO. Named to the 2019 Forbes 30 Under 30 Europe list for Science and Healthcare, his expertise centers on leveraging artificial intelligence and machine learning to advance computational biology, high-throughput genomic analysis, and drug discovery.